---
category: listing
circular_id: e79eb5a7c0ac2f56
date: '2025-11-20'
description: BSE announces allocation of 45,27,823 equity shares to 25 anchor investors
  at ₹593 per share for Sudeep Pharma Limited's IPO, raising ₹268.50 crore.
draft: false
guid: https://www.bseindia.com/markets/MarketInfo/DispNoticesNCirculars.aspx?Noticeid={BA9149B9-6AB5-4D1A-B8BD-829B7F89C215}&noticeno=20251120-55&dt=11/20/2025&icount=55&totcount=56&flag=0
impact: medium
impact_ranking: medium
importance_ranking: medium
justification: Important IPO anchor allocation for pharmaceutical company, significant
  for investors tracking new listings and pharma sector, but limited broader market
  impact
pdf_url: https://www.bseindia.com/markets/MarketInfo/DownloadAttach.aspx?id=20251120-55&attachedId=33965bd9-ff25-4c54-8c2a-baf5e4440095
processing:
  attempts: 1
  content_hash: 266bd49e638725b4
  processed_at: '2025-11-20T15:29:03.116873'
  processor_version: '2.0'
  stage: completed
  status: published
published_date: '2025-11-20T14:36:57+00:00'
rss_url: https://www.bseindia.com/markets/MarketInfo/DispNoticesNCirculars.aspx?Noticeid={BA9149B9-6AB5-4D1A-B8BD-829B7F89C215}&noticeno=20251120-55&dt=11/20/2025&icount=55&totcount=56&flag=0
severity: medium
source: bse
stocks:
- SUDEEPPHRM
tags:
- anchor-investor
- equity
- ipo
- pharma-sector
- public-issue
- sudeep-pharma
title: Public Issue of Sudeep Pharma Limited - Allocation to Anchor Investors
---

## Summary

BSE has announced the allocation of equity shares to anchor investors for Sudeep Pharma Limited's initial public offering (IPO). The Board of Directors finalized the allocation of 45,27,823 equity shares of face value ₹1 each to 25 anchor investors at an allocation price of ₹593 per share (including share premium of ₹592), raising a total of ₹268.50 crore in the anchor investor portion.

## Key Points

- Total anchor allocation: 45,27,823 equity shares at ₹593 per share
- Total amount raised from anchors: ₹268.50 crore (₹2,68,49,99,039)
- Face value: ₹1 per equity share
- Share premium: ₹592 per equity share
- Number of anchor investors: 25 investors
- Domestic allocation: 36,05,799 shares (79.64% of anchor portion) to 14 domestic investors
- Book Running Lead Managers: ICICI Securities Limited and IIFL Capital Limited (formerly IIFL Securities Limited)
- Board meeting date: November 20, 2025

## Major Anchor Investors

### Largest Allocations (7.82% each):
- SBI Healthcare Opportunities Fund: 3,54,125 shares (₹21.00 crore)
- ICICI Prudential MNC Fund: 3,54,125 shares (₹21.00 crore)
- Nippon Life India Trustee Ltd - Nippon India Flexi Cap Fund: 3,54,125 shares (₹21.00 crore)
- Aditya Birla Sun Life Small Cap Fund: 3,54,125 shares (₹21.00 crore)
- Mirae Asset Healthcare Fund: 2,04,900 shares (₹12.15 crore)

### Other Significant Allocations:
- Axis Multi Asset Allocation Fund: 2,65,600 shares (₹15.75 crore)
- HDFC Manufacturing Fund: 2,36,075 shares (₹14.00 crore)
- Multiple mutual funds and insurance companies with allocations ranging from 51,212 to 2,04,900 shares

## Company Information

- Company Name: Sudeep Pharma Limited
- CIN: U24231GJ1989PLC013141
- Registered Office: 129/1/A, G.I.D.C. Estate Nandesari, Baroda-391340, Gujarat
- Corporate Office: 601-602, 6th Floor, Sears Towers-2, Gotri-Sevasi Road, Sevasi, Vadodara-390021, Gujarat
- Website: www.sudeepgroup.com
- Email: mail@sudeepgroup.com
- Phone: +91 265 2840656, 7624095107

## Important Dates

- Board Meeting Date: November 20, 2025
- Anchor Investor Allocation Date: November 20, 2025

## Impact Assessment

### Market Impact:
- Strong institutional interest with participation from major mutual funds including SBI, HDFC, ICICI Prudential, Axis, Whiteoak Capital, and others
- Healthcare/pharma sector focus evident from specialized healthcare funds participation (SBI Healthcare, Mirae Asset Healthcare, UTI Healthcare)
- Broad diversification across fund categories: small cap, flexi cap, multi cap, manufacturing, and sector-specific funds
- Insurance participation from SBI Life and Tata AIA Life indicates confidence in the offering

### For Investors:
- Anchor allocation represents institutional validation of the IPO pricing
- Price point at ₹593 per share serves as reference for retail and other investor categories
- Strong presence of quality institutional investors may indicate positive sentiment for main IPO

### Sector Relevance:
- Pharmaceutical manufacturing sector company based in Gujarat
- Addition to listed pharma companies on BSE/NSE
- Potential index inclusion candidate post-listing